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Abstract
Numerous missense mutations in the presenilins are associated with the autosomal dominant form of familial Alzheimer
disease. Presenilin genes encode polytopic transmembrane proteins, which are processed by proteolytic cleavage and form
high-molecular-weight complexes under physiological conditions. The presenilins have been suggested to be functionally
involved in developmental morphogenesis, unfolded protein responses and processing of selected proteins including the
L-amyloid precursor protein. Although the underlying mechanism by which presenilin mutations lead to development of
Alzheimer disease remains elusive, one consistent mutational effect is an overproduction of long-tailed amyloid L-peptides.
Furthermore, presenilins interact with L-catenin to form presenilin complexes, and the physiological and mutational effects
are also observed in the catenin signal transduction pathway. ß 2000 Elsevier Science B.V. All rights reserved.
Keywords: Alzheimer disease; Presenilin; L-Amyloid precursor protein; Notch 1; L-Catenin; Armadillo; Secretase; Amyloid-L peptide;
Tau
1. Introduction
The pathogenesis of Alzheimer disease (AD) is
complex [1], and the common clinical and neuropa-
thological features can arise from several di¡erent
genetic and non-genetic causes. Nevertheless, there
is a certain proportion of AD cases (V10%) which
appear to be transmitted as a pure autosomal dom-
inant trait with age-dependence but high penetrance.
Molecular genetic analysis of these pedigrees has led
to the discovery of four AD-related genes, namely L-
amyloid precursor protein (LAPP), apolipoprotein E
(ApoE), presenilin 1 (PS1) and presenilin 2 (PS2).
After the discovery that LAPP missense mutations
and the ApoE polymorphisms did not account for
all cases of familial Alzheimer disease (FAD), a ser-
ies of polymorphic markers on chromosome 14q24.3
was revealed to be linked to a particularly aggressive
early onset form of FAD. PS1 was then cloned as a
causative gene in this locus [2]. In this review, we
focus on recent progress of studies on PS biology
and its relationship to AD pathogenesis.
0925-4439 / 00 / $ ^ see front matter ß 2000 Elsevier Science B.V. All rights reserved.
PII: S 0 9 2 5 - 4 4 3 9 ( 0 0 ) 0 0 0 2 8 - 4
* Corresponding author. Fax: +1-416-978-1878;
E-mail : paul.fraser@utoronto.ca
BBADIS 61944 3-7-00 Cyaan Magenta Geel Zwart
Biochimica et Biophysica Acta 1502 (2000) 1^15
www.elsevier.com/locate/bba
2. PS1 expression and pathological mutations
PS1 is highly conserved in evolution, being present
also in Caenorhabditis elegans and Drosophila and is
transcribed at low levels in many tissues, both within
the central nervous system (CNS) and in non-neuro-
nal organs [3,4]. In the CNS, PS1 transcripts can be
detected in the neocortex (especially in layers II and
IV), in the CA1^CA3 ¢elds, dentate gyrus and sub-
iculum of the hippocampus and in the cerebellar cor-
Fig. 1. Primary sequence of PS1 indicating the contiguous hydrophobic sequences and potential TM domains. Con¢rmed TM domains
1 through 6 (TM1^6) are indicated as well as the other hydrophobic domains 7^10 (HD7^10). The endoproteolytic site in the vicinity
of codon 290 is indicated (*) as well as the caspase cleavage site at Asp-345. Missense mutation associated with FAD are shown in
bold below the sequence as well as the exon 10 deletion (O- - -O) and the insertion mutation between codons 113 and 114. The pro-
posed armadillo/catenin binding site within residue 372^399 is underlined.
BBADIS 61944 3-7-00 Cyaan Magenta Geel Zwart
P.E. Fraser et al. / Biochimica et Biophysica Acta 1502 (2000) 1^152
tex and deep nuclei, as well as lesser amounts in the
olfactory bulb, striatum, thalamus and some brain-
stem nuclei [4].
The PS1 protein is approximately 50 kDa in size
(longest form 467 residues; see Fig. 1) and is pre-
dominantly located in intracellular membranous or-
ganelle such as endoplasmic reticulum (ER), nuclear
envelope and Golgi apparatus [5]. In developing neu-
rons, PSs are expressed during the early stages of
di¡erentiation and are localized primarily to the
cell body but also display a punctate staining sug-
gesting distribution in, as yet, unidenti¢ed cytoplas-
mic vesicles [6,7]. In addition, PS immunoreactivity is
found in extending neurites and is concentrated to
the growth cone possibly indicating a role for the
PSs in synaptic formation and/or stabilization [6,8].
PS1 is extended into axons and dendrites as shown
by immuno£uorescence (Fig. 2 and [6]). Fractiona-
tion studies have indicated that the PSs are restricted
to intracellular compartments with a de¢ned endo-
proteolytic pattern during ER to Golgi transit [9].
However, more recent surface-labelling studies have
suggested that the PSs may be tra⁄cked to the plas-
ma membrane [10]. Although this remains controver-
sial, given the fact that the PS-related amyloid path-
way (see below) extends into the late Golgi it is
possible that the PSs are more widely distributed
than previously thought.
To date, more than 50 di¡erent pathologic muta-
tions have been reported in the PS1 gene [2,11^46].
The majority are missense mutations and are pre-
dominantly located in highly conserved TM do-
mains; at/near putative membrane interfaces; or in
the large hydrophilic Loop (Fig. 1 and Table 1). All
of the mutations occur at sites that are highly con-
served and are found in both PS1 and PS2 with the
exception of a Glu-to-Lys substitution at codon 123
in PS1 [20]. Only one nonpathogenic mutation of a
Glu-to-Gly at residue 318 has been observed [43]. In
addition, two splicing defect mutations have been
identi¢ed. One involves a point mutation in the splice
acceptor site at the 5P end of exon 10 (the numbering
of exon is followed by Rogaev et al. [47]), and allows
exon 9 to be fused in-frame with exon 11, thereby
removing a series of charged residues at the apex of
the large hydrophilic loop domain. Interestingly, this
mutation removes residues near the endoproteolytic
cleavage site at residue 290 and results in the increase
of uncleaved holoprotein (see below, and the amino
acid number is of the longest PS1). The second splice
site mutation arises from deletion of a G nucleotide
from the splice donor site at the 3P end of exon 5.
This results in the production of three unique tran-
scripts, two deletion transcripts and one insertion
transcript which introduces a Thr between residues
113 and 114 [14].
3. PS structure, topology and the endoproteolytic
cleavages
Hydrophobicity analysis has clearly demonstrated
that the PSs are multispanning transmembrane (TM)
proteins [2]. PS1 has 10 hydrophobic domains that
represent potential TM helices indicated as TM1^6
and hydrophobic domains 7^10 (HD7^10, Fig. 1). In
addition, two principal non-membrane regions are
contained within the highly acid N-terminus and a
Fig. 2. Immuno£uorescence of PS1 in a mouse hippocampal
neuron. PS1 was probed with a Loop-speci¢c antiserum (green)
and the neuron is double-labelled for the dendritic marker, mi-
crotubule-associated protein 2 (MAP2) (red). Overlap of the
two proteins indicates that PS1 is located in dendrites and the
axon containing the punctate, possibly vesicular structures (ar-
rows) as well as concentrated at extending growth cones (ar-
rowheads).
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Table 1
PS1 FAD mutations (citations indicated as references)
Residue Location Mutation References
79 N-term loop AlaCVal [11]
82 TM1 ValCLeu [12]
96 TM1 ValCPhe [13]
113, 114 TM1CTM2 loop Leu-IleCLeu-Thr-Ile [14]
115 TM1CTM2 loop TyrCHis [12]
115 TM1CTM2 loop TyrCCys [11]
116 TM1CTM2 loop ThrCAsn [15]
117 TM1CTM2 loop ProCLeu [16]
120 TM1CTM2 loop GluCAsp, Lys [17^19]
123 TM1CTM2 loop GluCLys [20]
135 TM2 AsnCAsp [21]
139 TM2 MetCThr, Lys [12,13]
139 TM2 MetCVal, Ile [22,23]
143 TM2 IleCThr, Phe [12,24]
146 TM2 MetCLeu, Ile, Val [2,23,25]
147 TM2 ThrCIle [26]
163 TM3 interface HisCArg, Tyr [23,27]
165 TM3 interface TrpCCys [26]
169 TM3 interface SerCLeu, Pro [28,29]
171 TM3 LeuCPro [30]
173 TM3 LeuCTrp [26]
177 TM3 PheCSer a
178 TM3 SerCPro a
206 TM4 interface GlyCSer a
209 TM4 interface GlyCVal, Arg [12,20]
213 TM4 interface IleCThr, Leu [13]a
219 TM4 interface LeuCPro [31]
222 TM5 GlnCAla a
231 TM5 AlaCThr [12]
233 TM5 MetCThr [32]
235 TM5 LeuCPro [33]
246 TM6 AlaCGlu [2]
250 TM6 AlaCSer [34]
260 TM6 AlaCVal [35]
261 TM6 ValCPhe a
262 TM6 LeuCPhe [36]
263 Cytoplasmic loop CysCArg [37]
264 Cytoplasmic loop ProCLeu [12]
267 Cytoplasmic loop ProCSer [24]
269 Cytoplasmic loop ArgCGly, His [38,39]
278 Cytoplasmic loop ArgCThr [32]
280 Cytoplasmic loop GluCAla, Gly [24]
282 Loop/HD7 LeuCArg [40]
285 Loop/HD7 AlaCVal [35]
286 Loop/HD7 LeuCVal [2]
v291^319 Loop/HD7 Truncated loop [41,42]
318 Cytoplasmic loop GluCGlyb [19,43]
378 Cytoplasmic loop GlyCGlu [44]
384 HD8 GlyCAla [45]
390 HD8 SerCIle [26]
392 HD8 LeuCVal [12]
410 HD9 CysCTyr [2]
418 HD9 LeuCPhe [4]
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hydrophilic ‘Loop’ domain located in the C-terminal
portion of the sequence. Secondary structure predic-
tive algorithms indicate that the N-terminus is highly
£exible with a few short segments in an K-helical
conformation with the Loop domains predicted to
be a compact bundle of 5-6 K-helices. This confor-
mations have been con¢rmed by spectroscopic anal-
ysis of recombinant fragments of both PS1 and PS2
(unpublished results).
Examination of PS topology has revealed that the
N-terminus and the Loop are both oriented to the
cytoplasm while the hydrophilic linking sequence be-
tween TM1 and TM2 is, as predicted, located within
the ER/Golgi lumen [5,48,49]. This con¢rms that the
initial six hydrophobic domains (TM1^6) are indeed
TM helices and that the hydrophobic domain 7
(HD7) is likely to be membrane-associated rather
than a TM helix. Although a 6 TM model of PS1
has been proposed [48], the remaining three hydro-
phobic stretches (HD7^9) are potential TM domains
which could result in a 7, 8 or 9 TM protein. The 7
and 9 TM model would produce a lumenal orienta-
tion of the C-terminus and a cytoplasmic orientation
in the 8 TM model. One line of evidence suggests
that the C-terminus is located in the cytoplasm and
that the hydrophobic domain, indicated as HD8 and
HD9, represent TM domains 7 and 8 respectively
[5,48,49]. In this model, the ¢nal hydrophobic do-
main (HD10) is membrane-associated. This is in con-
trast to a recent study using a systematic series of
PS1-fusion proteins which suggests that the C-termi-
nus is oriented within the lumen in support of a 7 TM
model [51]. In support of this model, it has been
demonstrated that the catenin binding site on PS1
is located within the region containing the HD8 do-
main [50]. These data suggest that this domain is
located in the cytoplasmic space to allow for bind-
ing with the non-membranous armadillo proteins.
Although the topology of the C-terminus has yet to
be completely resolved, these analyses are consistent
with the PSs having a compact series of TM domains
with the bulk of the hydrophilic regions oriented
within the cytoplasmic space (Fig. 3). In this case,
the N-terminus and Loop would be available for
interactions with potentially functional binding pro-
teins.
Analysis of the PS1 transcript suggests the pres-
ence of some splicing variants. Thus, there is a var-
iably present four-amino acid VRQS insert which
arises from use of an alternate splice donor site at
the 3P end of exon 4. In some tissues (especially leu-
kocytes), there is also alternate splicing of exon 9
which encodes a series of hydrophobic residues at
the C-terminus of TM6 and the beginning of the
cytoplasmic Loop domain. As a result, this splicing
event is predicted to signi¢cantly alter the functional
properties of the Loop, and along with physiological
endoproteolytic cleavage in the Loop domain (see
below), is one of the arguments which suggests that
it represents a key sequence that mediates the biolog-
ical function of the PSs.
Studies of the PS1 protein in brain tissue, as well
as many other peripheral tissues, reveal that only
very small amounts of the holoprotein exist within
the cell at any given time [52,53]. Instead, the holo-
protein is actively catabolized, possibly by at least
two di¡erent proteolytic mechanisms. One of these
mechanisms appears to involve the proteasome [54].
Another mechanism involves a series of heterogene-
ous endoproteolytic cleavages near residue 290 with-
in the Loop domain [52,53]. This cleavage by ‘prese-
nilase’ generates N- and C-terminal fragments of
approximately 35 and 20 kDa, respectively. Remark-
ably, the stoichiometry of the N- and C-terminal
Table 1 (continued)
Residue Location Mutation References
424 HD9 LeuCArg [46]
426 HD9 AlaCPro [20]
431 HD9-10 loop AlaCGlu a
434 HD10 AlaCCys a
436 HD10 ProCSer, Gln [24]
439 HD10 IleCVal a
aRogaeva, E., St George-Hyslop, P., unpublished.
bPotentially non-pathogenic mutation.
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fragments is maintained on a 1:1 ratio and their
absolute abundance is also tightly regulated such
that arti¢cial overexpression of PS1 results in only
a modest increase in these fragments [52]. This has
led to the suggestion that this physiological proteo-
lytic cleavage involves a tightly regulated saturable
process [55]. A third mechanism involves members
of the caspase 3 family. Activation of the apoptotic
pathway which culminates in activation of caspase 3
results in cleavage of PS1 near residue aspartate 345
[56^58]. It is currently unclear whether caspase cleav-
age of PSs is actively involved in the regulation of
apoptosis, or whether PSs simply represent innocent
bystanders, although preliminary data suggest an
anti-apoptotic e¡ect for the C-terminal derivative
by caspase [59]. Certainly, caspase-mediated cleavage
is not required for the e¡ects on amyloidogenesis and
Notch signalling (see below).
Fig. 3. A hypothetical molecular model showing the TM helices embedded within the membrane and the cytoplasmically oriented
N-terminus and Loop domains. Availability of these exposed domains for interactions with potential binding proteins is also indi-
cated.
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4. PSs in high-molecular-weight membrane-bound
complexes
Whether the holoprotein, the physiologic proteo-
lytic fragments or both have biological activities is
currently unclear. However, it is clear that the holo-
protein and its endoproteolytic fragments are com-
ponents of high-molecular-weight protein complexes.
Thus, the holoprotein appears to be a component of
an V180 kDa complex which is predominantly res-
ident in the rough ER [8,55,60]. The N- and C-ter-
minal fragments appear to associate with each other
as heterodimeric components of a larger (V250
kDa) multimeric protein complex that appears to
be resident in the ER, Golgi, and some additional
membranous domains whose identity has not been
clari¢ed [8,55,60]. The latter may include detergent-
insoluble glycosphingolipid-rich domains (lipid-rich
rafts) [61]. The incorporation of PS proteins into a
larger complex represents a rate limiting step in the
PS processing pathway [62,63]. Thus, once incorpo-
rated into these high-molecular-weight complexes,
the endoproteolytic fragments remain together with
a stable 1:1 stoichiometry and with very long half-
lives. Holoprotein monomers which fail to get incor-
porated into these complexes are rapidly degraded
with a half-life of less than 1 h via a proteasome-
dependent mechanism [62]. Studies have suggested
that this incorporation into the protein complexes
seems necessary for a biological activity in APP pro-
cessing [64].
The identity of the other components of the PS
complexes is currently under investigation. However,
a combination of yeast-two-hybrid, co-immunopre-
cipitation, immunohistochemistry, and subcellular
fractionation studies reveal that in peripheral tissues
and, in brain, PSs associate with L-catenin, a member
of the armadillo protein superfamily [9,50,65]. In
brain, PS1 and PS2 also associate with a novel arm
protein termed neuronal plakophillin-related arma-
dillo protein (NPRAP) or N-catenin [9,50,65]. A can-
didate arm-protein-binding domain has been de¢ned
to residues 372^399 in PS1 (Fig. 1) [50]. This domain
contains a single arm-like motif which is highly con-
served in PS2 and also in the invertebrate homo-
logues. In addition, PS1 binds to another NPRAP/
N-catenin related protein called, p0071, but the bio-
logical signi¢cance is unknown [50,66]. Recent re-
ports indicate that the ability of PS1 to bind with
L-catenin is abolished by caspase cleavage, suggesting
that caspase-cleaved fragments are not incorporated
into PS complexes and might not be fully functional
[67]. There is evidence from some laboratories that
the PSs may also interact directly with LAPP [68,69].
However, contradictory ¢ndings on PS1:LAPP inter-
actions suggest that this ¢nding remains to be re-
solved [55].
5. Biological functions of PS
The physiological function of PS1 has not yet been
de¢ned. However, functional analogies have been
made to a nematode homologue spe-4, which is in-
volved in maintenance of a Golgi-derived membra-
nous organelle thought important in partitioning of
protein and cell membrane products in the maturing
spermatocyte [70]. This has led to speculation that
PS1 might subserve a similar role in protein and
membrane tra⁄cking. This hypothesis is supported
by several di¡erent lines of experimental evidence.
For example, this function of the PSs is supported
by the fact that their multimeric complexes with
L-catenin and missense mutations in PS1 and PS2
cause perturbation of nuclear translocation of this
PS ligand [71]. But perhaps more importantly for
AD pathology, ablation of functional PS1 expression
causes aberrant processing of LAPP with the failure
of Q-secretase cleavage, which results in the accumu-
lation of uncleaved K-secretase or L-secretase stubs in
a variety of intracellular loci including ER, Golgi,
and lysosomes [72,73]. Similar ¢ndings were observed
for an APP homolog, APLP1, which has a limited
sequence identity in the TM region including the
Q-secretase sites. This fact supports a hypothesis
that the PS-de¢ciency alters tra⁄cking of proteolytic
C-terminal fragments of APP and APLP1 to speci¢c
subcellular compartments which contain ‘Q-secretase
activity’, rather than the alternative speculation that
the PSs play a direct role in APP processing by
Q-secretase [74]. However, the alternate possibility
that the PSs have direct protease activity has also
been proposed. Based on the 8 TM model, it was
suggested that two membrane-embedded aspartates
(residues 257 and 385) constitute an aspartyl protease
catalytic site that is responsible both for PS endopro-
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teolysis and the Q-secretase activity [75]. While this
remains an intriguing possibility, the precise relation-
ship between the PSs and LAPP cleavage have yet to
be clari¢ed.
Other putative functions for PS1 include roles in
the regulation of signal transduction during develop-
ment, in apoptosis, and possibly in cellular calcium
ion homeostasis. The former suggestion arose be-
cause null mutations in a second PS orthologue of
C. elegans (sel-12) exert a suppressor e¡ect on abnor-
malities in vulva progenitor cell fate decisions in-
duced by activated Notch mutants [3]. Notch is in-
volved in intercellular signalling during development.
In fact, sel-12 shows stronger amino acid sequence
identity to the human PS than does spe-4. PS e¡ects
on Notch signalling is further supported by the fact
that targeted disruption of the murine PS1 gene
causes embryonic lethality around day E13 and is
associated with: (1) severe developmental defects in
somite formation and axial skeleton formation (2)
the occurrence of cerebral hemorrhage, and (3) re-
duced Notch1 and Dll1 transcription in selected cell
types [76,77]. Similar phenotypes have been observed
in knockout mice for Notch1 and Dll1, also support-
ing this hypothesis. It has also been demonstrated
that PS1 regulates the proteolytic processing of
Notch in a similar manner to that of APP as well
as nuclear translocation of the Notch intracellular
fragment [78^80]. E¡ects were also noted for mutant
Drosophila PS which resulted in altered Notch pro-
cessing.
The PS-based mechanism of these events is under
investigation and more recently it has been reported
that PS1 is a regulator of the unfolded protein re-
sponse (UPR) [81,82]. The UPR is an intracellular
signalling pathway linking the ER and the nucleus in
response to the accumulation of unfolded proteins in
the ER lumen. Induction of the UPR pathway in-
volves the proteolytic cleavage of a TM kinase, Ire1,
followed by nuclear accumulation of its fragment. As
with APP and Notch, cells derived from PS1 null
mice exhibit a reduction in UPR and Ire1 nuclear
translocation. In addition to Ire1, the UPR induces
the transcription of a number of other ER factors
such as Bip (or GRP78) whose expression is reduced
by FAD-related mutations in PS1. The role for PSs
in this central stress-response pathway suggest that
they are key elements in the overall cellular degrada-
tion and removal of misfolded proteins within the
ER.
6. Pathological mechanism of PS1 mutations to AD
The dominant inheritance mode and wide scatter-
ing of missense mutations has led to speculation that
the e¡ect of the FAD-related mutations is a ‘gain of
function’ e¡ect. This is partially borne out by two
observations in PS1 knockout mice. First, these mice
have a phenotype of perinatal lethality without evi-
dence of AD [76,77]. This ‘loss of function’ pheno-
type can be completely rescued not only by wild-type
but also by mutant PS1 transgenes [83,84]. Second,
PS1-de¢cient mice have a defect in LAPP processing
manifest by the failure of Q-secretase cleavage [72]. A
gain of function is imparted by the mutant trans-
genes because it also induces an increase in the amy-
loid-L terminating at residue 42 (AL42) which, as
described below, is a consistent biochemical e¡ect
of PS1 mutations [83,84]. However, a very di¡erent
perspective is provided by complementation assays of
mutant sel-12 in C. elegans. The wild-type human
PS1, but not mutant human PS1 are able to comple-
ment the loss-of-function sel-12 mutants [85,86], sug-
gesting that the human PS1 mutants may not be fully
functional in nematode.
One de¢nitive e¡ect of PS1 (and PS2) mutations is
to alter the processing of LAPP by preferentially fa-
voring the production of potentially toxic long-tailed
AL peptides ending at residue 42 or 43 (AL42 or
AL43) which are ¢brillogenic and early deposits in
the patient brains [87^91]. Fibroblasts from hetero-
zygous carriers of PS1 mutations, various cell lines
transfected with LAPP and PS1 cDNAs, as well as
brains from mutant PS1-transgenic mice all contain
or secrete increased quantities of AL42 with only a
variable but minor increase in short-tailed AL pep-
tides (AL40) [87^91]. Direct measurements of AL iso-
forms in the post-mortem brain tissue of patients
dying with PS1-linked FAD also show marked in-
creases in the amount of AL42 compared to control
brain tissue and to brain tissue from subjects with
sporadic AD [92]. This e¡ect of mutant PS1 seems to
represent a ‘gain of function’ mode.
While a substantial body of work suggests that
defective processing of LAPP and overproduction
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of AL42 is intimately associated with PS mutations,
PS mutations also may modulate cellular sensitivity
to apoptosis induced by a variety of factors including
exposure to AL peptides and NGF withdrawal [93^
95]. At the current time these data are still evolving
and the apparent paradox of a putative ‘apoptosis
promoting e¡ect’ for the PSs and the viability of
PS-transgenic mice lacking excessive apoptosis re-
mains to be explained.
7. Normal and mutational e¡ects of PSs in the
L-catenin signalling pathway
The functional signi¢cance of PS:armadillo inter-
actions is not entirely clear, because the armadillo
proteins have diverse functions ranging from a struc-
tural role in stabilization of intercellular junctions
(including synapses), in signal transduction of Wnt
and certain growth factors and in apoptotic path-
ways [96]. However, some recent reports suggest
the physiological and mutational e¡ects of PSs in
the L-catenin signalling pathway (Fig. 4). Zhang et
al. [97] showed that the formation of PS1:L-catenin
complex led to increased stability of L-catenin. Fur-
thermore, pathogenic mutant PS1 loses this stabiliza-
tion e¡ect, and cause suppression of L-catenin signal-
ling. Conversely, our data indicated that the PS
function in this pathway is not clear under physio-
logical conditions. However, pathogenic mutant PSs
a¡ect on the downstream to free L-catenin stabiliza-
tion and perturb their nuclear translocation in a
‘gain of aberrant function’ mode [71]. Additionally,
PS1 has been reported to have the ability to bind
microtubule-associated protein tau and glycogen syn-
thase kinase-3L (GSK-3L) [98]. And the mutant PS1
facilitates phosphorylation of tau by GSK-3L,
although another report does not support this ¢nd-
ing [99]. How these mutational e¡ects are related to
AD pathogenesis is an important future issue.
8. Presenilin-2
During the cloning of PS1 a homologue PS2 gene
was identi¢ed in the nucleotide sequence databases
and was revealed to be mapped on chromosome
1q42.1 [100,101]. The amino acid sequence identity
between PS2 and PS1 is approximately 60% as a
whole and about 90% within the TM domains. How-
ever, the pattern of transcription was slightly di¡er-
ent, being expressed less homogeneously in the brain
and in peripheral tissues. PS2 is maximally expressed
in cardiac muscle, skeletal muscle and pancreas. The
predicted topology of PS2 protein is similar to that
of PS1, and it also forms a similar but independent
multimeric protein complex which contains L-catenin
[9,60].
Genetic analyses uncovered two di¡erent missense
mutations in PS2. The ¢rst mutation (Asn141Ile;
Asn-135 in PS1) was detected in a proportion of
Fig. 4. Putative PS e¡ects in L-catenin signalling pathway. The
major intracellular pool of L-catenin is a cadherin-bound form,
and a cytoplasmic free form is rather minor but mediates im-
portant signal transduction such as Wnt/wingless pathway.
Without stimulation by Wnt ligand, free L-catenin is phosphor-
ylated by GSK-3L, then ubiquitinated and rapidly degraded by
proteasome. Upon activation of Wnt pathway, GSK-3L activity
is inhibited, and free L-catenins increase and translocate into
the nucleus to activate the downstream genes. GSK-3L also
phosphorylates tau protein, and the hyperphosphorylation of
tau could lead to formation of neuro¢brillary tangles in AD
brains. The mediating positions of frizzled (Fz) and disheveled
(Dsh) in the pathway are also shown.
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families of Volga German ancestry [100,101]. The
second mutation (Met239Val; Met-233 in PS1) was
discovered in an Italian pedigree [100]. However, in
contrast to the frequency of PS1 mutations, screen-
ing of large data sets reveals that PS2 mutations are
likely to be rare. The phenotype associated with PS2
mutations is much more variable than that with PS1
mutations. While the range of age-of-onset is be-
tween 35 and 65 years for patients with PS1 muta-
tions, the range in PS2-linked patients is between 40
and 85 years, and there is at least one instance of
apparent non-penetrance in an asymptomatic octo-
genarian transmitting the disease to a¡ected o¡-
spring.
The functional relationship of PS2 to PS1 remains
unknown. Although both proteins reside within the
ER, Golgi and nuclear envelope, they appear to form
distinct high-molecular-weight complexes [9,55], and
their tissue-speci¢c patterns of expression are di¡er-
ent [100,101]. Nevertheless, given the strong similar-
ities in structure and in amino acid sequence, it
would seem likely that PS1 and PS2 have similar
or overlapping activities. This is supported by the
fact that PS2 mutations also increase the secretion
of long-tailed AL peptides [88,91]. PS2 mutations
may also cause increased sensitivity to apoptosis,
but it is unclear whether this is an e¡ect independent
of their ability to cause increased AL peptide secre-
tion [93,94].
9. Conclusions and perspectives
AD research appears to be standing at the turning
point. Recently an intriguing hypothesis has been
proposed, raised mainly from the research on inher-
ited diseases with trinucleotide repeats. That is, the
majority of adult-onset neurodegenerative disorders
might be commonly caused by progressive precipita-
tion of proteolysis-resistant protein(s) speci¢c for
each disease [102]. In the case of AD, the causative
precipitates are composed of AL peptides (cores of
senile plaques) or hyperphosphorylated tau proteins
(neuro¢brillary tangles). Given that this hypothesis is
true, a key role of the PSs leading to AD develop-
ment could be solely an overproduction of long-
tailed AL peptides whatever the physiological func-
tions or the other mutational e¡ects of the PSs. Be-
cause both homologous molecules PS1 and PS2
cause AD, investigations into the PSs is likely to
provide powerful clues to resolve pathways culminat-
ing in AD-related neurodegeneration.
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